LexaGene Announces Results of Annual General Shareholder’s Meeting
November 13 2020 - 5:00PM
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the
“
Company”), a molecular diagnostics company that
develops fully automated rapid pathogen detection systems, is
pleased to announce the voting results of the Company’s 2020 Annual
General Shareholder’s Meeting held on November 10, 2020 in
Vancouver, British Columbia.
A total of 48,273,080 common shares were voted at the Meeting,
representing 42.26% of the votes attached to all outstanding common
shares of the Company.
All matters presented for shareholder approval at the Meeting
were duly authorized and approved as follows:
- To set the number of Directors to be elected at five.
- Election of Directors.
- To re-appoint Manning Elliot LLP, Chartered Professional
Accountants as the Company’s auditors for the ensuing year.
- Increase the number of Common Shares available for conversion
of Restricted Share Units.
- Increase the number of Common Shares available for exercise of
Options.
Detailed voting results for the election of directors were as
follows:
Name |
Shares Voted For |
% |
Shares Withheld / Abstain |
% |
Dr. John (Jack) Regan |
22,117,120 |
97.03 |
677,427 |
2.97 |
Daryl Rebeck |
22,705,522 |
95.22 |
1,089,025 |
4.78 |
Thomas Richard Slezak |
22,691,362 |
99.55 |
103,185 |
0.45 |
Dr. Manohar Furtado |
22,717,615 |
99.66 |
76,932 |
0.34 |
Joseph Caruso |
22,494,351 |
98.68 |
300,196 |
1.32 |
To be added to the LexaGene email list, please subscribe on the
Company website.
On Behalf of the Board of DirectorsDr.
Jack ReganChief Executive Officer
& Director
About LexaGene Holdings Inc.LexaGene is a
molecular diagnostics company that develops molecular diagnostic
systems for pathogen detection and genetic testing for other
molecular markers for on-site rapid testing in veterinary
diagnostics, food safety and for use in open-access markets such as
clinical research, agricultural testing and biodefense. End-users
simply need to collect a sample, load it onto the instrument with a
sample preparation cartridge, enter sample ID and press ‘go’. The
MiQLab™ system delivers excellent sensitivity, specificity, and
breadth of detection and can return results in approximately one
hour. The unique open-access feature is designed for custom testing
so that end-users can load their own real-time PCR assays onto the
instrument to target any genetic target of interest.
For further information, please contact:
Media ContactsNicole RidgedaleDirector of
Corporate Marketing, LexaGene800.215.1824 ext
206nridgedale@lexagene.com
Investor RelationsJay AdelaarVice President of
Capital Markets, LexaGene800.215.1824 ext
207jadelaar@lexagene.com
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024